| Title |
Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies
|
|---|---|
| Published in |
Drugs, November 2017
|
| DOI | 10.1007/s40265-017-0830-1 |
| Pubmed ID | |
| Authors |
Julie Dyall, Robin Gross, Jason Kindrachuk, Reed F. Johnson, Gene G. Olinger, Lisa E. Hensley, Matthew B. Frieman, Peter B. Jahrling |
| Abstract |
No specific antivirals are currently available for two emerging infectious diseases, Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). A literature search was performed covering pathogenesis, clinical features and therapeutics, clinically developed drugs for repurposing and novel drug targets. This review presents current knowledge on the epidemiology, pathogenesis and clinical features of the SARS and MERS coronaviruses. The rationale for and outcomes with treatments used for SARS and MERS is discussed. The main focus of the review is on drug development and the potential that drugs approved for other indications provide for repurposing. The drugs we discuss belong to a wide range of different drug classes, such as cancer therapeutics, antipsychotics, and antimalarials. In addition to their activity against MERS and SARS coronaviruses, many of these approved drugs have broad-spectrum potential and have already been in clinical use for treating other viral infections. A wealth of knowledge is available for these drugs. However, the information in this review is not meant to guide clinical decisions, and any therapeutic described here should only be used in context of a clinical trial. Potential targets for novel antivirals and antibodies are discussed as well as lessons learned from treatment development for other RNA viruses. The article concludes with a discussion of the gaps in our knowledge and areas for future research on emerging coronaviruses. |
X Demographics
The data shown below were collected from the profiles of 179 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 27 | 15% |
| France | 21 | 12% |
| Netherlands | 3 | 2% |
| Belgium | 2 | 1% |
| Poland | 2 | 1% |
| Canada | 2 | 1% |
| United Kingdom | 2 | 1% |
| Curaçao | 1 | <1% |
| Ireland | 1 | <1% |
| Other | 11 | 6% |
| Unknown | 107 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 172 | 96% |
| Scientists | 4 | 2% |
| Practitioners (doctors, other healthcare professionals) | 2 | 1% |
| Science communicators (journalists, bloggers, editors) | 1 | <1% |
Mendeley readers
The data shown below were compiled from readership statistics for 256 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 256 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 35 | 14% |
| Student > Bachelor | 33 | 13% |
| Student > Master | 29 | 11% |
| Researcher | 24 | 9% |
| Student > Doctoral Student | 15 | 6% |
| Other | 41 | 16% |
| Unknown | 79 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 38 | 15% |
| Biochemistry, Genetics and Molecular Biology | 37 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 15 | 6% |
| Chemistry | 11 | 4% |
| Agricultural and Biological Sciences | 10 | 4% |
| Other | 43 | 17% |
| Unknown | 102 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 156. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 March 2024.
All research outputs
#267,480
of 25,784,004 outputs
Outputs from Drugs
#22
of 3,485 outputs
Outputs of similar age
#5,320
of 336,945 outputs
Outputs of similar age from Drugs
#1
of 21 outputs
Altmetric has tracked 25,784,004 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,485 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.1. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 336,945 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.